非处方口服避孕药市场－全球产业规模、份额、趋势、机会和预测：按药片类型、类别、分销管道、地区和竞争格局划分，2021-2031年

全球非处方口服避孕药市场预计将从 2025 年的 179 亿美元大幅成长至 2031 年的 297.6 亿美元，复合年增长率为 8.84%。

这些非处方药通常只含黄体素，消费者无需医生处方笺即可获得荷尔蒙避孕药。这些药片透过增稠子宫颈黏液来阻止精子进入并抑制排卵，为生殖健康管理提供了一种便捷的方法。推动这一市场发展的主要因素是全球法规结构的转变，该转变允许从处方药过渡到非处方药，从而增强了消费者的自主权并减轻了医疗机构的后勤负担。这种可近性提高的趋势正在支撑全球需求的成长，世界卫生组织（WHO）的数据显示，到2024年，全球77.1%的育龄妇女将使用现代方法满足其计划生育需求，这便是最好的证明。

儘管存在这些积极因素，但市场仍面临一个重大障碍：非处方药的保险报销不一致。消费者需要自付部分费用，这可能会让对价格敏感的消费者望而却步，尤其是在医疗补贴取决于是否有正式处方笺的地区。因此，即使产品供应充足，此经济障碍也会限制低收入族群的市场渗透率，并阻碍市场进一步扩张。

市场驱动因素

越来越多的监管机构核准将处方药转换为非处方药（OTC），这正在改变市场格局，因为这样就无需医生介入购买过程。这种监管转变使得製造商能够直接向消费者提供孕激素单药疗法，从而提高用户便利性并减轻医疗保健系统的负担。这种商业性效应在新核准产品的策略定价中得到了清晰的体现，旨在促进大众市场接受度。例如，该公司在2024年3月发布的新闻稿中宣布，其在美国推出的首个非处方口服避孕药「Opil」的建议零售价为19.99美元（一个月用量）。这是该公司在获得FDA核准后旨在促进产品普及的策略。

此外，电子商务和线上药局通路的扩张是重要的次要驱动因素，监管方面的进步确保了实体和数位管道的广泛普及。透过将销售融入主流零售环境，市场正在克服传统的物流和隐私障碍。这个广泛的分销网络在满足全球计划生育需求方面发挥着至关重要的作用。联合国人口基金（UNFPA）估计，到2024年，购买的避孕药具将预防约1,800万例意外怀孕。公共卫生模型也反映了这一分销管道的成长规模。英国卫生与社会保障部确认，英格兰已有3,000家药局完成註册，可直接向民众供应口服避孕药，如《药学杂誌》2024年1月刊所述。

市场挑战

非处方口服避孕药市场商业性成长的主要障碍之一是缺乏稳定的健保报销机制。随着这些产品从处方笺药转变为非处方笺药，第三方支付方的报销往往消失，将全部经济负担转嫁到购买者身上。这种成本负担的转移构成了一项直接的经济障碍，限制了价格敏感族群的接受度。儘管监管政策的调整改善了购买管道，但需要自费购买使得那些先前依赖全额补贴处方药的潜在用户犹豫不决。

这种报销差异导致市场分散，使製造商无法全面了解市场需求。由于各州的保险覆盖要求各不相同，产品的可及性往往更多地取决于地理位置而非医疗需求。凯撒家庭基金会2024年的报告凸显了这个问题，报告显示，美国祇有七个州立法强制要求州监管的私人医疗保险计划涵盖非处方笺避孕药。这项数据表明，这些产品的资金支持基础分散，直接限制了市场渗透率，并在立法框架未能跟上产品供应速度的地区抑制了收入成长。

市场趋势

订阅式补货模式的兴起正在从根本上改变消费行为，将购买习惯从一次性交易转变为持续互动。这种模式透过自动化补货解决了维持口服避孕药使用的关键挑战，并降低了意外停药的可能性，同时确保了製造商的长期客户维繫。透过将产品与自动化配送和虚拟助理结合，这些服务避免了传统药房取药带来的许多不便，并吸引了重视隐私和便利的消费者。消费者健康平台的扩张证明了这个策略的成功。根据 Investing.com 2025 年 11 月的报告，Hims & Hers Health 的个人化订阅服务用户已达到约 250 万，年成长 21%。

同时，用于合格筛检的行动医疗应用程式的引入，正在建立一个先进的数位基础设施，从而实现安全获取非处方药。与传统的电子商务网站不同，这些应用程式使用演算法调查问卷即时确定禁忌症，并模拟临床分诊流程，无需面对面咨询。这种数位化柔软性使得企业能够在维持医疗安全标准的同时，快速回应市场需求波动。 Femtech Insider 在 2025 年 1 月报告的一个案例凸显了这种技术主导方法的敏捷性：远端医疗提供者 Wisp 在一次关键的政治变革发生前一周，事后紧急避孕药的销售环比激增 233%，这凸显了数位筛检平台在实现即时市场进入发挥的关键作用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球非处方口服避孕药市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 避孕药类型（黄体素片、复方片）
  • 按类别（非专利、品牌商品）
  • 分销通路（线下、线上）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美非处方口服避孕药市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲非处方口服避孕药市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区非处方口服避孕药市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲非处方口服避孕药市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲非处方口服避孕药市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球非处方口服避孕药市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Mylan NV
• Nurx Inc.
• Everly Well, Inc.
• Letsgetchecked Inc.
• Uqora, Inc.
• Hims & Hers Health, Inc.
• Lemonaid Health, Inc.
• Perrigo Company plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Over the Counter (OTC) Contraceptive Pills Market is projected to expand significantly, rising from USD 17.90 Billion in 2025 to USD 29.76 Billion by 2031, reflecting a CAGR of 8.84%. These over-the-counter medications, generally comprising progestin-only formulations, allow consumers to obtain hormonal contraception without a prescription from a healthcare provider. By thickening cervical mucus to impede sperm and suppressing ovulation, these pills provide a streamlined method for managing reproductive health. A primary catalyst for this market is the global shift in regulatory frameworks enabling Rx-to-OTC switches, which enhances consumer autonomy and alleviates logistical pressures on clinical facilities. This trend toward greater accessibility supports growing global demand, evidenced by World Health Organization data from 2024 showing that 77.1% of women of reproductive age worldwide had their family planning needs met through modern methods.

Despite these positive drivers, the market faces a substantial obstacle regarding the inconsistent insurance reimbursement for non-prescription drugs. The necessity of covering out-of-pocket expenses can discourage price-sensitive buyers, particularly in regions where healthcare subsidies depend on having a formal prescription. Consequently, this financial barrier restricts market penetration among lower-income demographics, impeding broader expansion despite the availability of the products.

Market Driver

The increasing number of regulatory approvals for Prescription-to-OTC switches is transforming the market by eliminating the need for physician intervention in the purchasing process. This regulatory shift encourages manufacturers to introduce progestin-only options directly to consumers, thereby simplifying the user journey and lessening the demand on medical systems. The commercial effect is visible in the strategic pricing of these newly approved products, which targets mass-market adoption. For instance, Perrigo Company plc announced in a March 2024 press release regarding 'Opill First Over-The-Counter Birth Control In The U.S.' that the suggested retail price for a one-month supply was set at $19.99, a strategy aimed at encouraging widespread use following the FDA's approval.

Furthermore, the expansion of e-commerce and online pharmacy channels acts as a crucial secondary driver, ensuring these regulatory advancements result in broad physical and digital availability. By incorporating sales into mainstream retail environments, the market overcomes previous logistical and privacy-related obstacles. This extensive distribution network plays a key role in fulfilling global family planning requirements; the United Nations Population Fund estimated in 2024 that procured contraceptives averted approximately 18 million unintended pregnancies. The magnitude of this channel growth is also evident in public health models, as highlighted by Pharmacy Magazine in January 2024, which noted the Department of Health and Social Care's confirmation that 3,000 pharmacies in England had registered to supply oral contraception directly to the public.

Market Challenge

A significant impediment to the commercial growth of the over-the-counter contraceptive pills market is the absence of consistent insurance reimbursement for non-prescription medications. When these products move from prescription-only status to retail shelves, third-party payer coverage frequently disappears, transferring the full financial responsibility to the buyer. This shift in cost establishes an immediate economic hurdle that restricts adoption among price-sensitive groups. Even with improved physical access due to regulatory changes, the necessity for point-of-sale out-of-pocket payments discourages potential users who previously depended on fully subsidized prescription alternatives.

This gap in reimbursement causes market fragmentation and hinders manufacturers from capturing the full extent of demand. Because coverage mandates vary, accessibility often depends on geographic location rather than medical necessity. Highlighting this issue, the Kaiser Family Foundation reported in 2024 that only seven U.S. states had enacted laws requiring state-regulated private health insurance plans to cover over-the-counter contraception without a prescription. This statistic emphasizes the fragmented financial support landscape for these products, which directly limits market penetration and suppresses revenue growth in regions where legislative frameworks have not kept pace with product availability.

Market Trends

The rise of subscription-based replenishment models is fundamentally changing consumer behavior by transitioning purchasing habits from one-off transactions to recurring engagements. This approach tackles the vital challenge of adherence to oral contraception by automating refills, thereby reducing the chance of unintended usage gaps and ensuring long-term customer retention for manufacturers. By combining products with automated delivery and virtual assistance, these services circumvent the logistical inconveniences of traditional pharmacy visits, appealing to consumers who value privacy and convenience. The success of this strategy is demonstrated by the expansion of direct-to-consumer health platforms; as reported by Investing.com in November 2025, Hims & Hers Health saw its subscriber base for personalized recurring treatments increase by 21% year-over-year to approximately 2.5 million users.

Simultaneously, the incorporation of mobile health applications for eligibility screening is establishing a sophisticated digital framework that facilitates safe over-the-counter access. Unlike conventional e-commerce sites, these applications employ algorithmic questionnaires to instantly identify contraindications, mimicking the clinical triage process without the need for a physical medical appointment. This digital flexibility enables the market to quickly adapt to shifts in public demand while maintaining medical safety standards. The agility of this technology-driven method was underscored when Femtech Insider reported in January 2025 that telehealth provider Wisp saw a 233% week-over-week surge in emergency contraception sales prior to significant political transitions, illustrating the vital function of digital screening platforms in enabling immediate market access.

Key Market Players

• Mylan N.V.
• Nurx Inc.
• Everly Well, Inc.
• Letsgetchecked Inc.
• Uqora, Inc.
• Hims & Hers Health, Inc.
• Lemonaid Health, Inc.
• Perrigo Company plc

Report Scope

In this report, the Global Over the Counter (OTC) Contraceptive Pills Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Over the Counter (OTC) Contraceptive Pills Market, By Pill Type

• Progestin Pills
• Combination Pills

Over the Counter (OTC) Contraceptive Pills Market, By Category

• Generic
• Branded

Over the Counter (OTC) Contraceptive Pills Market, By Distribution Channel

• Offline
• Online

Over the Counter (OTC) Contraceptive Pills Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Over the Counter (OTC) Contraceptive Pills Market.

Available Customizations:

Global Over the Counter (OTC) Contraceptive Pills Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Over the Counter (OTC) Contraceptive Pills Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Pill Type (Progestin Pills, Combination Pills)
  • 5.2.2. By Category (Generic, Branded)
  • 5.2.3. By Distribution Channel (Offline, Online)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Over the Counter (OTC) Contraceptive Pills Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Pill Type
  • 6.2.2. By Category
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Pill Type
      • 6.3.1.2.2. By Category
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Pill Type
      • 6.3.2.2.2. By Category
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Pill Type
      • 6.3.3.2.2. By Category
      • 6.3.3.2.3. By Distribution Channel

7. Europe Over the Counter (OTC) Contraceptive Pills Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Pill Type
  • 7.2.2. By Category
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Pill Type
      • 7.3.1.2.2. By Category
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Pill Type
      • 7.3.2.2.2. By Category
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Pill Type
      • 7.3.3.2.2. By Category
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Pill Type
      • 7.3.4.2.2. By Category
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Pill Type
      • 7.3.5.2.2. By Category
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Over the Counter (OTC) Contraceptive Pills Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Pill Type
  • 8.2.2. By Category
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Pill Type
      • 8.3.1.2.2. By Category
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Pill Type
      • 8.3.2.2.2. By Category
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Pill Type
      • 8.3.3.2.2. By Category
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Pill Type
      • 8.3.4.2.2. By Category
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Pill Type
      • 8.3.5.2.2. By Category
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Over the Counter (OTC) Contraceptive Pills Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Pill Type
  • 9.2.2. By Category
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Pill Type
      • 9.3.1.2.2. By Category
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Pill Type
      • 9.3.2.2.2. By Category
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Pill Type
      • 9.3.3.2.2. By Category
      • 9.3.3.2.3. By Distribution Channel

10. South America Over the Counter (OTC) Contraceptive Pills Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Pill Type
  • 10.2.2. By Category
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Pill Type
      • 10.3.1.2.2. By Category
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Pill Type
      • 10.3.2.2.2. By Category
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Over the Counter (OTC) Contraceptive Pills Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Pill Type
      • 10.3.3.2.2. By Category
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Over the Counter (OTC) Contraceptive Pills Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Mylan N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Nurx Inc.
• 15.3. Everly Well, Inc.
• 15.4. Letsgetchecked Inc.
• 15.5. Uqora, Inc.
• 15.6. Hims & Hers Health, Inc.
• 15.7. Lemonaid Health, Inc.
• 15.8. Perrigo Company plc

16. Strategic Recommendations

17. About Us & Disclaimer